Research progress of Yttrium 90 in the treatment of unresectable and chemotherapy tolerant colorectal liver metastasis

Colorectal liver metastasis (CRLM) is a common liver metastatic tumor with poor prognosis. It was very difficult to treat patients with unresectable and chemotherapy tolerant CRLM. With the tumor control rate ranging from 63% to 78%, Yttrium-90 is both safe and effective in treating unresectable and chemotherapytolerant CRLM. The median survival time is 10.5 months, and the 1, 2, 3 year overall survival rates of patients are 44%, 20% and 14% respectively. For a certain portion of patients, Yttrium-90 has distinct advantages over molecular targeted drugs and other local minimally invasive treatment. Though Yttrium90 treatment has showed certain curative effect, its safety and effectiveness require further confirmation through multicenter randomized controlled trial.